Back

Anti-inflammation, PCSK9 inhibition, or both?

11 April 2019 (09:15 - 09:37)
Organised by:
Congress Presentation Part of: Targeting inflammation in atherosclerosis: burning questions Lipids EAPC Premium Access EuroPrevent 2019

About the speaker

Photo
Professor Jose Tunon Fernandez

Fundacion Jimenez Diaz University Hospital, Madrid (Spain)

3 More presentations in this session

Presentation thumbnail
Are there hidden powers in omega-3 fatty acids?
Professor M. Back (Stockholm, SE)
Video
Presentation thumbnail
Inflammation, exercise and atrial fibrillation
Doctor A. Elliott (Adelaide, AU)
Slides Video
Presentation thumbnail
Anti-inflammatory secondary prevention: what’s next?
Doctor G. Caligiuri (Paris, FR)
Slides Video

Access the full session

Session thumbnail
Targeting inflammation in atherosclerosis: burning questions

The Event

Event poster

EuroPrevent 2019

11 April 2019 09:15 CET
You may be interested in
thumbnail
Congress Presentation
The effect of proprotein convertase subtilisin/kexin type 9 inhibition on the plasma proteome: a SPIRE sub-study
28 August 2023
thumbnail
Webinar
Quantification of coronary inflammation using coronary CT angiography to improve patient risk prediction and stratification
27 September 2021
thumbnail
Congress Presentation
GLP1-RA associated with PCSK9i as chemosensitizing method and therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidences
20 June 2025
thumbnail
Congress Presentation
Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources